International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology

@article{Neubig2003InternationalUO,
  title={International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology},
  author={Richard R. Neubig and Michael Spedding and Terry Kenakin and Arthur Christopoulos},
  journal={Pharmacological Reviews},
  year={2003},
  volume={55},
  pages={597 - 606}
}
The recommendations that follow have been updated from the proposals of a Technical Subcommittee set up by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, and Shankley NP (1995) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47:255–266). 
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
TLDR
The International Union of Basic and Clinical Pharmacology/British Pharmacological Society (IUPHAR/BPS) Guide to PHARMACOLOGY is a new open access resource providing pharmacological, chemical, genetic, functional and pathophysiological data on the targets of approved and experimental drugs. Expand
International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands
TLDR
An overview of allostery as applied to receptor families and approaches for detecting and validating allosteric interactions is presented and recommendations for the nomenclature ofAllosteric ligands and their properties are given. Expand
Drug-Target Association Kinetics in Drug Discovery.
TLDR
This review provides a compilation and discussion of otherwise scarce and dispersed information on this topic, bringing to light the importance of drug-target association in kinetics-directed drug design and discovery. Expand
The fall and rise of pharmacology--(re-)defining the discipline?
TLDR
The integration of newer technologies within a pharmacological context where research is driven by testable hypotheses rather than technology, together with renewed efforts in teaching pharmacology, is anticipated to improve the focus and relevance of biomedical research and lead to novel therapeutics that will contain health care costs. Expand
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
TLDR
This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015, and introduces the newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org). Expand
Overview of Drug Discovery and Development
This overview unit describes the core activities involved in the drug discovery and development process, from target identification ‐ including preclinical biology, medicinal and process chemistry ‐Expand
Principles of pharmacodynamics and their applications in veterinary pharmacology.
TLDR
This review introduces and summarizes the principles of PDs and illustrates them with examples drawn from both basic and veterinary pharmacology. Expand
The Hill equation and the origin of quantitative pharmacology
This review addresses the 100-year-old Hill equation (published in January 22, 1910), the first formula relating the result of a reversible association (e.g., concentration of a complex, magnitude ofExpand
Link between a high k on for drug binding and a fast clinical action: to be or not to be?
TLDR
The presented simulations tally with a positive link between a drug's effective/observed association rate and the swiftness of its clinical action, and show that the k on-concept should not be confounded with the effective association process. Expand
Molecular and cellular analysis of human histamine receptor subtypes.
TLDR
Current knowledge of hH(x)Rs endogenously expressed in human cells and recombinantly expressed in mammalian and insect cells is summarized and multiple systems and parameters have to be studied to increase drug safety and efficacy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
International Union of Pharmacology. XXXI. Recommendations for the Nomenclature of Multimeric G Protein-Coupled Receptors
A receptor is defined by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) as a protein, or a complex of proteins, which recognizesExpand
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
This issue of Pharmacological Reviews includes a new venture in the collaboration between the International Union of Pharmacology (IUPHAR) and the American Society for Pharmacology and ExperimentalExpand
A Pharmacologic Analysis of Drug-Receptor Interaction
Drug receptor/theory seven transmembrane receptor behaviour human recombinant receptor systems stimulus-response mechanisms drug response mechanisms diffusion and drug concentration in receptorExpand
A modification of receptor theory.
  • R. P. Stephenson
  • Chemistry, Medicine
  • British journal of pharmacology and chemotherapy
  • 1956
TLDR
An attempt has been made to determine the relation between log concentration and effect for acetylcholine and the frog rectus abdominis after blocking the cholinesterase activity of isolated rabbit auricles. Expand
Operational models of pharmacological agonism
  • J. Black, P. Leff
  • Psychology, Medicine
  • Proceedings of the Royal Society of London. Series B. Biological Sciences
  • 1983
TLDR
An alternative model is proposed, representing the cognitive and transducer functions of a receptor, that describes agonist action with one fewer parameter than the traditional model, and provides a chemical definition of intrinsic efficacy making this parameter experimentally accessible in principle. Expand
pA, a new scale for the measurement of drug antagonism.
  • H. Schild
  • Chemistry, Medicine
  • British journal of pharmacology and chemotherapy
  • 1947
TLDR
This is the first of a set of three papers in the Journal that were to transform the study of drug antagonism and Schild proposed and validated a new measure of antagonist action, pA, and showed how pAx measurements could provide a reproducible and statistically satisfactory index of the effectiveness of an antagonist action. Expand
Analysis of competitive agonist-antagonist interactions by nonlinear regression.
  • M. Lew, J. Angus
  • Mathematics, Medicine
  • Trends in pharmacological sciences
  • 1995
TLDR
A simplified global regression method with improved accuracy compared to Schild analysis is described, suitable for personal computers with standard graphing and statistical software. Expand
SOME QUANTITATIVE USES OF DRUG ANTAGONISTS
TLDR
Various applications of pAx measurements are discussed based on the hypothesis that drugs and drug antagonists compete for receptors according to the mass law, and a new measure, pAh, is introduced to express the activity of unsurmountable antagonists. Expand
The ligand paradox between affinity and efficacy: can you be there and not make a difference?
TLDR
All ligands with macro-affinity should be extensively studied for pharmacological activities other than simple G-protein activation with the potential promise of discovering new therapeutic applications for old drugs. Expand
Further analysis of anomalous pKB values for histamine H2‐receptor antagonists on the mouse isolated stomach assay
TLDR
It is concluded that the apparent varying selectivity of the antagonists for gastric and atrial histamine H2‐receptors may be explained by the differential loss of antagonists into the gastric secretion from the receptor compartment and that there is no need to postulate heterogeneity of histamineH2‐ receptors. Expand
...
1
2
3
4
...